GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release and Management & Discussion Analysis11-08-2023
11-08-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Change in Directorate
Re-appointment of Ms. Sona Saira Ramasastry (DIN 08398547) as Non-Executive Independent Director11-08-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Unaudited Financial Results (Standalone And Consolidated) For The First Quarter Ended 30Th June, 2023
Unaudited Financial Results (Standalone and Consolidated) for the First Quarter ended 30th June, 202311-08-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Minutes Of The Resolution Passed By Way Of Postal Ballot Through Remote E-Voting
Enclosing the minutes of the resolution passed by Postal Ballot09-08-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Result Of Postal Ballot By Remote E-Voting & Scrutinizer'S Report
Voting Result as required under Regulation 44(3) of SEBI Listing Regulations and Scrutinizers Report 202304-08-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Monday, August 14, 2023 at 9:30 a.m. - 10:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.04-08-2023
Glenmark Pharma shares gain on US FDA nod for Saxagliptin tablets
A meeting of the board of directors will be held on August 11, 2023, to consider and approve the unaudited financial results of the company for the first quarter ended June 30, 2023.01-08-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Saxagliptin Tablets01-08-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window
Intimation for closure of trading window.31-07-2023
GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The First Quarter Ended June 30, 2023.
GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the First quarter ended June 30, 2023.31-07-2023